Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-1065846 · 1 trial · 2 indications
The DARS is a dynamic scale that measured desire, motivation, effort and consummatory pleasure across hedonic domains. The DARS is a self-report questionnaire that measured anhedonia across 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. The DARs was rated on a five-point Likert scale from 0 (not at all) to 4 (very much), higher values indicating less anhedonia. All items were summed up to a total score in the range of 0 to 68.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participant follows Placebo schedule (57 days) |
| Antidepressant | EXPERIMENTAL | Participant follows NBI-1065846 schedule (57 days) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets for oral administration |
| NBI-1065846 | DRUG | Tablets for oral administration |
Key Inclusion Criteria: Participants must meet all of the following key inclusion criteria: 1. Completed written informed consent. 2. Aged 18 to 65 years, inclusive, at the time of informed consent. 3. Primary diagnosis of MDD. 4. Participants must meet one of the following criteria: * must ha...
NBI-1065846 is an investigational small molecule being developed for the treatment of anhedonia, a core symptom of major depressive disorder (MDD). It is being studied in patients with anhedonia and MDD. The drug is administered orally once weekly and is currently in Phase 2 clinical development.
NBI-1065846 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NBIX. The company is conducting clinical trials to evaluate the efficacy and safety of this investigational drug for anhedonia in major depressive disorder.
NBI-1065846 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. A Phase 2 study evaluating its efficacy and safety in anhedonia associated with major depressive disorder has been completed.
NBI-1065846 has been studied in one completed Phase 2 clinical trial, identified as NCT05165394. This randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of once-weekly oral NBI-1065846 in the treatment of anhedonia in major depressive disorder. The trial enrolled 93 participants in the United States and Puerto Rico.
NBI-1065846 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a small molecule being developed by Neurocrine Biosciences for the treatment of anhedonia in major depressive disorder.